Doctors will keep checking B12 levels to adjust doses
Patients receiving semaglutide (0.5 or 1.0 mg) for 104 weeks demonstrated a significantly higher risk of diabetic retinopathy complications, including vitreous hemorrhage, blindness, or required procedural treatment compared to those receiving placebo (HR, 1.76
As an investigational compound with no FDA-approved therapeutic dosing guidelines, these figures derive exclusively from research literature and should not be interpreted as clinical recommendations
Jill Carnahan, MD Sort of metabolic risk, 100, brain health, cancer risk, cardiovascular health, depression, anxiety, insomnia
Future research directions Conduct RCT studies to verify its efficacy and safety in diseases such as IBD and gastric ulcers